A detailed history of Balyasny Asset Management LLC transactions in Merus N.V. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 598,888 shares of MRUS stock, worth $25.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
598,888
Previous 585,024 2.37%
Holding current value
$25.4 Million
Previous $34.6 Million 13.56%
% of portfolio
0.05%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $654,242 - $815,757
13,864 Added 2.37%
598,888 $29.9 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $23.3 Million - $35.2 Million
585,024 New
585,024 $34.6 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $7.48 Million - $10.7 Million
372,879 Added 43.34%
1,233,238 $33.9 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $17.3 Million - $23.5 Million
860,359 New
860,359 $20.3 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.95B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.